Jane Street
CRSP icon

Jane Street’s CRISPR Therapeutics CRSP Stock Holding History

Jane Street’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.4M Buy
576,000
+14,600
+3% +$770K ﹤0.01% 1514
2025
Q4 		$29.4M Buy
561,400
+203,100
+57% +$12.2M ﹤0.01% 1278
2025
Q3 		$23.2M Buy
358,300
+137,500
+62% +$7.89M ﹤0.01% 1519
2025
Q2 		$10.7M Buy
220,800
+50,400
+30% +$1.95M ﹤0.01% 2067
2025
Q1 		$5.8M Buy
170,400
+123,600
+264% +$5.24M ﹤0.01% 2721
2024
Q4 		$1.84M Sell
46,800
-16,000
-25% -$756K ﹤0.01% 4258
2024
Q3 		$2.95M Sell
62,800
-157,900
-72% -$8.01M ﹤0.01% 3743
2024
Q2 		$11.9M Sell
220,700
-88,300
-29% -$5.11M ﹤0.01% 1829
2024
Q1 		$21.1M Sell
309,000
-388,500
-56% -$27.8M ﹤0.01% 1147
2023
Q4 		$43.7M Buy
697,500
+522,600
+299% +$28.9M 0.01% 752
2023
Q3 		$7.94M Sell
174,900
-213,700
-55% -$11M ﹤0.01% 2044
2023
Q2 		$21.8M Buy
388,600
+157,200
+68% +$8.92M 0.01% 1134
2023
Q1 		$10.5M Sell
231,400
-25,100
-10% -$1.22M ﹤0.01% 1592
2022
Q4 		$10.4M Sell
256,500
-173,800
-40% -$9.22M ﹤0.01% 1572
2022
Q3 		$28.1M Buy
430,300
+7,800
+2% +$565K 0.01% 829
2022
Q2 		$25.7M Sell
422,500
-63,700
-13% -$3.74M 0.01% 933
2022
Q1 		$30.5M Buy
486,200
+179,700
+59% +$11.3M 0.01% 962
2021
Q4 		$23.2M Buy
306,500
+135,300
+79% +$11.8M 0.01% 1086
2021
Q3 		$19.2M Sell
171,200
-207,100
-55% -$26M 0.01% 1170
2021
Q2 		$61.2M Sell
378,300
-39,900
-10% -$4.85M 0.02% 464
2021
Q1 		$51M Buy
418,200
+11,400
+3% +$1.72M 0.03% 478
2020
Q4 		$62.3M Buy
406,800
+251,700
+162% +$29.8M 0.03% 383
2020
Q3 		$13M Sell
155,100
-28,300
-15% -$2.51M 0.01% 1032
2020
Q2 		$13.5M Buy
183,400
+172,600
+1,598% +$10.1M 0.01% 989
2020
Q1 		$458K Sell
10,800
-7,000
-39% -$361K ﹤0.01% 3713
2019
Q4 		$1.08M Buy
+17,800
New +$972K ﹤0.01% 2667
2018
Q3 		– Sell
-12,500
Closed -$735K – 5155
2018
Q2 		$735K Buy
+12,500
New +$712K ﹤0.01% 3141

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jane Street's CRSP Position: Q2 2025 in Review

Jane Street sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 237,128 shares — an estimated $9.18M sold.

Jane Street first reported a position in CRSP in Q1 2018 and held it in 28 quarters. The position peaked at $66.7M in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Jane Street reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jane Street sold 237,128 CRISPR Therapeutics shares in Q2 2025, an estimated $9.18M.
  • Jane Street first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 28 quarters.
  • Jane Street's CRISPR Therapeutics position peaked at $66.7M in Q2 2021.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Jane Street's 13F filing for Q2 2025, filed 14 Aug 2025.